Patents by Inventor Kevin Wayne Kuntz

Kevin Wayne Kuntz has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Quinazolinones as PARP14 inhibitors
    Patent number: 11958837
    Abstract: The present invention relates to quinazolinones and related compounds which are inhibitors of PARP14 and are useful, for example, in the treatment of cancer and inflammatory diseases.
    Type: Grant
    Filed: April 14, 2021
    Date of Patent: April 16, 2024
    Assignee: Ribon Therapeutics, Inc.
    Inventors: Laurie B. Schenkel, Melissa Marie Vasbinder, Kevin Wayne Kuntz, Kerren Kalai Swinger
  • Quinolines and azaquinolines as inhibitors of CD38
    Patent number: 11952377
    Abstract: The present invention relates to bicyclic heterocycle compounds of Formula (I): and pharmaceutically acceptable salts thereof, which are inhibitors of CD38 and are useful in the treatment of cancer.
    Type: Grant
    Filed: January 28, 2022
    Date of Patent: April 9, 2024
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Jennifer Downing, Kevin Wayne Kuntz, Laurie B. Schenkel, Melissa Marie Vasbinder
  • TARGETED PROTEIN DEGRADATION OF PARP14 FOR USE IN THERAPY
    Publication number: 20240101540
    Abstract: The present invention relates to quinazolinones and related compounds which degrade PARP14 and are useful, for example, in the treatment of cancer and inflammatory diseases.
    Type: Application
    Filed: July 28, 2023
    Publication date: March 28, 2024
    Inventors: Nicholas Robert Perl, Kevin Wayne Kuntz, Jennifer Downing
  • TARGETED PROTEIN DEGRADATION OF PARP14 FOR USE IN THERAPY
    Publication number: 20240051946
    Abstract: The present invention relates to quinazolinones and related compounds which degrade PARP14 and are useful, for example, in the treatment of cancer and inflammatory diseases.
    Type: Application
    Filed: July 28, 2023
    Publication date: February 15, 2024
    Inventors: Nicholas Robert Perl, Kevin Wayne Kuntz
  • PYRIDAZINONES AS PARP7 INHIBITORS
    Publication number: 20240034728
    Abstract: The present invention relates to pyridazinones and related compounds which are inhibitors of PARP7 and are useful in the treatment of cancer.
    Type: Application
    Filed: May 12, 2023
    Publication date: February 1, 2024
    Inventors: Nicholas Robert Perl, Melissa Marie Vasbinder, Kevin Wayne Kuntz
  • HETEROBICYCLIC AMIDES AS INHIBITORS OF CD38
    Publication number: 20230312586
    Abstract: The present invention relates to heterobicyclic amides and related compounds which are inhibitors of CD38 and are useful in the treatment of cancer.
    Type: Application
    Filed: December 5, 2022
    Publication date: October 5, 2023
    Inventors: Laurie B. Schenkel, Melissa Marie Vasbinder, Kevin Wayne Kuntz, Nicholas Robert Perl, Jennifer Downing
  • SOLID FORMS OF A PARP14 INHIBITOR
    Publication number: 20230303542
    Abstract: The present invention relates to solid forms of the poly(ADP-ribose) polymerase 14 (PARP14) inhibitor 7-((1-acetylpiperidin-4-yl)methoxy)-5-fluoro-2-(((tetrahydro-2H-pyran-4-yl)thio)methyl)quinazolin-4(3H)-one, including methods of preparation thereof, where the inhibitor is useful in the treatment of cancer and inflammatory diseases.
    Type: Application
    Filed: February 8, 2023
    Publication date: September 28, 2023
    Inventors: Melissa Marie Vasbinder, Laurie B. Schenkel, Kerren Kalai Swinger, Kevin Wayne Kuntz, Nicholas Robert Perl, John Alphons Kremers, Zheng Jane Li, Pengyuan Chen
  • Pyridazinones as PARP7 inhibtors
    Patent number: 11691969
    Abstract: The present invention relates to pyridazinones and related compounds having Formula I: and pharmaceutically acceptable salts thereof, which are inhibitors of PARP7 and are useful in the treatment of cancer.
    Type: Grant
    Filed: October 29, 2020
    Date of Patent: July 4, 2023
    Assignee: Ribon Therapeutics, Inc.
    Inventors: Nicholas Robert Perl, Melissa Marie Vasbinder, Kevin Wayne Kuntz
  • PYRIDAZINONES AS PARP7 INHIBITORS
    Publication number: 20230192664
    Abstract: The present invention relates to pyridazinones and related compounds which are inhibitors of PARP7 and are useful in the treatment of cancer.
    Type: Application
    Filed: October 27, 2022
    Publication date: June 22, 2023
    Inventors: Melissa Marie Vasbinder, Laurie B. Schenkel, Kerren Kalai Swinger, Kevin Wayne Kuntz
  • Substituted benzene compounds
    Patent number: 11642348
    Abstract: The present invention relates to substituted benzene compounds. The present invention also relates to pharmaceutical compositions containing these compounds and methods of treating cancer by administering these compounds and pharmaceutical compositions to subjects in need thereof. The present invention also relates to the use of such compounds for research or other non-therapeutic purposes.
    Type: Grant
    Filed: July 9, 2020
    Date of Patent: May 9, 2023
    Assignee: Epizyme, Inc.
    Inventors: Kevin Wayne Kuntz, John Emmerson Campbell, Masashi Seki, Syuji Shirotori, Wataru Itano, Wanjun Zheng
  • SALT FORM OF A HUMAN HISTONE METHYLTRANSFERASE EZH2 INHIBITOR
    Publication number: 20230140327
    Abstract: Provided herein is N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-5-(ethyl (tetrahydro-2H-pyran-4-yl)amino)-4-methyl-4?-(morpholinomethyl)-[1,1?-biphenyl]-3-carboxamide hydrobromide. Also provided herein is a particular polymorph form of this compound.
    Type: Application
    Filed: September 29, 2022
    Publication date: May 4, 2023
    Inventors: Kevin Wayne KUNTZ, Kuan-Chun Huang, Hyeong Wook Choi, Kristen Sanders, Steven Mathieu, Arani Chanda, Francis Fang
  • SMYD Inhibitors
    Publication number: 20230101819
    Abstract: The present disclosure provides carboxamides and sulfonamides having Formula (I); and the pharmaceutically acceptable salts and solvates thereof, wherein A, Y, B, X, and Z are defined as set forth in the specification. The present disclosure is also directed to the use of compounds of Formula (I) to treat a disorder responsive to the blockade of SMYD proteins such as SMYD3 or SMYD2. Compounds of the present disclosure are especially useful for treating cancer.
    Type: Application
    Filed: November 22, 2021
    Publication date: March 30, 2023
    Inventors: Megan Alene Cloonan FOLEY, Kevin Wayne KUNTZ, James Edward John MILLS, Lorna Helen MITCHELL, Michael John MUNCHHOF, Darren Martin HARVEY
  • Pyridazinones as PARP7 inhibitors
    Patent number: 11566020
    Abstract: The present invention relates to pyridazinones and related compounds which are inhibitors of PARP7 and are useful in the treatment of cancer.
    Type: Grant
    Filed: April 12, 2021
    Date of Patent: January 31, 2023
    Assignee: Ribon Therapeutics, Inc.
    Inventors: Melissa Marie Vasbinder, Laurie B. Schenkel, Kerren Kalai Swinger, Kevin Wayne Kuntz
  • QUINAZOLINONES AS PARP14 INHIBITORS
    Publication number: 20230018702
    Abstract: The present invention relates to quinazolinones and related compounds which are inhibitors of PARP14 and are useful, for example, in the treatment of cancer and inflammatory diseases.
    Type: Application
    Filed: April 14, 2021
    Publication date: January 19, 2023
    Inventors: Laurie B. Schenkel, Melissa Marie Vasbinder, Kevin Wayne Kuntz, Kerren Kalai Swinger
  • Heterobicyclic amides as inhibitors of CD38
    Patent number: 11535621
    Abstract: The present invention relates to heterobicyclic amides and related compounds which are inhibitors of CD38 and are useful in the treatment of cancer.
    Type: Grant
    Filed: July 30, 2020
    Date of Patent: December 27, 2022
    Assignee: Ribon Therapeutics, Inc.
    Inventors: Laurie B. Schenkel, Melissa Marie Vasbinder, Kevin Wayne Kuntz, Nicholas Robert Perl, Jennifer Downing
  • TARGETED PROTEIN DEGRADATION OF PARP14 FOR USE IN THERAPY
    Publication number: 20220388985
    Abstract: The present invention relates to quinazolinones and related compounds which degrade PARP14 and are useful, for example, in the treatment of cancer and inflammatory diseases.
    Type: Application
    Filed: June 18, 2020
    Publication date: December 8, 2022
    Inventors: Laurie B. Schenkel, Melissa Marie Vasbinder, Kevin Wayne Kuntz, Kerren Kalai Swinger, Timothy J.N. Wigle
  • Salt form of a human histone methyltransferase EZH2 inhibitor
    Patent number: 11491163
    Abstract: Provided herein is N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-5-(ethyl (tetrahydro-2H-pyran-4-yl)amino)-4-methyl-4?-(morpholinomethyl)-[1,1?-biphenyl]-3-carboxamide hydrobromide. Also provided herein is a particular polymorph form of this compound.
    Type: Grant
    Filed: September 25, 2020
    Date of Patent: November 8, 2022
    Assignees: Epizyme, Inc., Eisai R&D Management Co., Ltd.
    Inventors: Kevin Wayne Kuntz, Kuan-Chun Huang, Hyeong Wook Choi, Kristen Sanders, Steven Mathieu, Arani Chanda, Francis Fang
  • COMBINATION THERAPY FOR TREATING CANCER
    Publication number: 20220281854
    Abstract: The present invention relates to compositions comprising inhibitors of human histone methyltransferase EZH2 and one or more other therapeutic agents, particularly anticancer agents such as prednisone, and methods of combination therapy for administering to subjects in need thereof for the treatment of cancer.
    Type: Application
    Filed: May 23, 2022
    Publication date: September 8, 2022
    Inventors: Heike KEILHACK, Sarah Kathleen KNUTSON, Kevin Wayne KUNTZ
  • METHODS OF TREATING INFLAMMATORY DISEASES
    Publication number: 20220265655
    Abstract: The present invention relates to use of quinazolinones and related compounds which are inhibitors of PARP14 for the treatment and prevention of an inflammatory disease.
    Type: Application
    Filed: January 28, 2022
    Publication date: August 25, 2022
    Inventors: Mario Niepel, Kevin Wayne Kuntz, Laurie B. Schenkel, Kerren Kalai Swinger, Melissa Marie Vasbinder
  • DOSAGE REGIMENS FOR PARP7 INHIBITORS
    Publication number: 20220265654
    Abstract: The present invention is directed to dosing, dosage regimens, formulations, unit dosage forms, and related, of a PARP7 inhibitor for the treatment of cancer. The present invention is also directed to methods of treating cancer by administering the PARP7 inhibitor in combination with an antibody that binds to PD-1.
    Type: Application
    Filed: February 15, 2022
    Publication date: August 25, 2022
    Inventors: Melissa Marie Vasbinder, Lucas J. Utley, Viviana Bozon, Kevin Wayne Kuntz, Sudha Parasuraman, William McCulloch, Nolan Wood